支气管哮喘治疗中糖皮质激素抵抗特征和9项评估

被引：7

作者：

刘勇

汤彦

机构：

[1] 暨南大学附属第一医院呼吸内科

来源：

实用医学杂志 | 2008年 / 11期

关键词：

D O I：

暂无

中图分类号：

R562.25 [];

学科分类号：

摘要：

<正>吸入糖皮质激素(ICS)已经成为支气管哮喘(哮喘)的首选治疗。大多数哮喘患者对糖皮质激素(glucocorticoid,GC)吸入和口服治疗反应良好,称为糖皮质激素敏感性哮喘(steroid sensitive asthma,SSA)。

引用

页码：1857 / 1859

页数：3

共 9 条

[1]

Determinants of future long-term asthma control [J].

Schatz, Michael ;

Zeiger, Robert S. ;

Vollmer, William M. ;

Mosen, David ;

Cook, E. Francis .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (05) :1048-1053

[2]

Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients [J].

Loke, Tuck-Kay ;

Mallett, Kirsty H. ;

Ratoff, Jonathan ;

O'Connor, Brian J. ;

Ying, Sun ;

Meng, Qiu ;

Soh, Cecilia ;

Lee, Tak H. ;

Corrigan, Chris J. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (02) :368-375

[3]

Update on glucocorticoid action and resistance [J].

Ito, K ;

Chung, KF ;

Adcock, IM .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (03) :522-543

[4]

Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma [J].

Bateman, Eric ;

Karpel, Jill ;

Casale, Thomas ;

Wenzel, Sally ;

Banerji, Donald .

CHEST, 2006, 129 (05) :1176-1187

[5]

p38 Mitogen-activated protein kinase–induced glucocorticoid receptor phosphorylation reduces its activity: Role in steroid-insensitive asthma.[J].Elvis Irusen;John G. Matthews;Atsushi Takahashi;Peter J. Barnes;Kian F. Chung;Ian M. Adcock.The Journal of Allergy and Clinical Immunology.2002, 4

[6]

热休克蛋白90和糖皮质激素受体比例失衡对哮喘患者T淋巴细胞凋亡的影响 [J].